Expanding Horizons: “Syngene – Cromos Pharma” Alliance Transforms Clinical Research We’re thrilled to announce our strategic alliance with Syngene! This partnership combines our expertise in offering high-quality execution and global coverage for clinical trials. Together, we simplify patient recruitment across the US, Europe, and India, while providing comprehensive clinical development services. Superior project management ensures seamless execution of global trials and unified project updates.
Successful Partnership Between MAIA Biotechnology and Cromos Pharma MAIA Biotechnology and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate. Read more in the press release: https://www.pr.com/press-release/914337
Cromos Pharma’s Agnieszka Milewska-Kranc Leads the Way in EU’s Rare Disease Advocacy In accordance with the Decision of the European Parliament and the Council of the EU establishing the Second Program of Action in the Field of Health, the EU Council Recommendation on Action in the Field of Rare Diseases was issued. This recommendation urges member states to establish and implement plans for rare diseases. The National
